Company Overview and News
AquaFun offers the following attractions: the aquatic gate, a 10-meter-wide arc with crashing waves; Pool Playground; Octopus and Jellyfish Sprinklers; Water Buckets and Spouts; Spray Grounds; and Water Pond.
RLC RBNTF RRETY RBLAY RRHI
THE BOURSE continued to reel from worrisome economic data that peppered this week, seesawing between muted gains and losses for much of Friday but ending relatively flat and capping recent week-on-week increases.
SMCP1 RBLAY SECB SMGBF SMC ALGGY PHSXY PSE SPHXF AGI SPHZF PSKXF SMGBY SMPH SMC2B SMC2A SMC2D RLC SMC2C SMC2F SPHXY SYBJF SMC2E ALGGF BBRRF BLOOM
JG Summit Holdings, Inc.’s attributable profit dropped by a third in the second quarter of 2018, as the weaker peso, higher fuel prices, as well as rising prices of raw materials for its food, airline, and chemical units tempered the double-digit increase in revenues.
JGSMY RLC JGS URC UVRBY RBLAY JGSHF UVRBF
E-commerce has made a significant impact in various industries including retail. With the growing appetite for convenient online shopping, a number of brick-and-mortar stores have been disrupted — with some even being forced out of business.
CAPITAL raised at the stock market reached a record P150 billion in the first half, as companies braved the local market amid prevailing volatility.
IRC PSKXF CHIB SUAFF RBLAY BSC DD CKGOY RLC PHSXY PSE FNI BCDTY
ROBINSONS LAND Corp. (RLC) is opening up one of its residential developments in the Bay Area to home-sharing online apps, seeking to capture the rising tourist market in the area.
ROBINSONS Land Corp. (RLC) is planning to develop a dormitory and shared office spaces in the future, seeking to cater to those who cannot afford to buy their own properties.
JG SUMMIT Holdings, Inc. is hiking its capital spending for 2018 as it aims to grow its petrochemical, airline, property, food and beverage, and banking businesses amid higher oil prices in the world market and the further depreciation of the peso.
JGSMY JGS RBNTF CEBUY UVRBY RBLAY CEBUF RLC RRETY URC CEB JGSHF UVRBF RRHI
ROXAS and Company, Inc. (RCI) expects its business ventures to stabilize in 2018, banking on its property projects and coconut processing plant to drive growth in the coming years.
RCI RLC RBLAY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to PSE:RLC / Robinsons Land Corporation on message board site Silicon Investor.
|Brillian (BRLC) - a Maker of LCoS for HDTV||Brillian (BRLC) - a Maker of LCoS for HDTV||Brillian (BRLC) - a Maker of LCoS for HDTV||RLCO: Realco, Inc.||RLCO: Realco, Inc.||RLCO: Realco, Inc.|